Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study
Table 4
The dynamics of plasma BDNF concentrations and main clinical characteristics in MNCD patients taking escitalopram.
Variables
MNCD-AD group ( = 10)
ScVMNCD group ( = 10)
Before treatment
After treatment
Before treatment
After treatment
Plasma BDNF concentrations, pg/mL
20660.4 ± 12774.6
26356.0 ± 8309.1
0.15
26652.4 ± 12435.7
30066.0 ± 10796.4
0.27
MMSE, score
26.5 (26-27)
28 (28-29)
0.005
25 (24–26)
27 (26–28)
0.005
Delayed recall, TIME test, number of words (0–5)
2 (1-2)
3.5 (3–5)
0.02
2.5 (2-3)
3 (1–4)
0.83
Verbal fluency, number of words during 3 min.
19.5 (15–25)
17.5 (12–24)
0.62
13 (10–17)
17 (10–19)
0.20
Clock drawing test, part I, score (0–10)
9 (8–10)
9 (8–10)
0.55
7 (7-8)
7.5 (6–9)
0.23
Kinetic apraxia, Luria’s tests, score (0–3)
0 (0-1)
0 (0-0)
0.22
2 (1–3)
2 (1-2)
0.48
NPI, total score (0–144)
11.5 (9–14)
6.5 (6–8)
0.0078
16.5 (9–18)
10.5 (7–13)
0.011
POMA, score (0–28)
25 (24–26)
25 (24–26)
1.0
15.5 (13–21)
16 (15–21)
0.043
BADL, score (0–60)
1 (1-1)
1 (0-1)
0.11
2 (1-2)
2 (1-2)
0.98
Data are presented as mean ± standard deviation/median (lower/upper quartile). : number of patients. , respectively: according to -test; by Wilcoxon criterion if not otherwise specified.
